Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 7 | 4 |
| List of Tables | 10 | 1 |
| List of Figures | 10 | 1 |
| Generic Growth Strategies - Introduction | 11 | 1 |
| Generic Growth Strategies - Market Overview | 12 | 11 |
| Overview of the Generics Market | 12 | 1 |
| Leading Generics Companies | 12 | 2 |
| Generics Market Share | 14 | 1 |
| Drivers and Restraints | 15 | 1 |
| Drivers | 16 | 1 |
| Patent Expiries | 16 | 2 |
| ANDA Applications and Approvals are on the Rise | 18 | 2 |
| Generic Drug Opportunities in the European Market | 20 | 1 |
| Restraints | 21 | 1 |
| Delayed Launch of Generic Equivalents | 21 | 1 |
| Less Profit Margin | 21 | 1 |
| Tender Systems Affect Generic Pricing | 21 | 1 |
| Lack of Regulations | 21 | 1 |
| Biosimilar Approvals Fall in the European Market | 22 | 1 |
| Generic Growth Strategies - Regulatory Landscape | 23 | 12 |
| The US | 23 | 1 |
| Hatch-Waxman Act and ANDA | 23 | 2 |
| Shortening Market Exclusivity of Biopharmaceuticals and Impact on Generics | 25 | 1 |
| Pay-For-Delay Ban to be Detrimental to Innovators as Well as Generics | 25 | 1 |
| Cost-sharing of Generic Drugs | 25 | 1 |
| Impact of Supplemental Examination Provision of Patent Reform Act on Generics | 26 | 1 |
| Biologics Price Competition and Innovation Act Falls Short | 26 | 1 |
| Biosimilarity Compared to Interchangeability | 27 | 1 |
| Biosimilar Approval Pathway | 27 | 1 |
| Patent Resolution | 28 | 1 |
| Europe | 28 | 1 |
| Generic Penetration | 28 | 1 |
| Generic Substitution | 29 | 1 |
| Pricing and Reimbursement | 29 | 1 |
| Marketing Authorization for Generics | 29 | 1 |
| Generic Landscape in Leading European Markets | 29 | 1 |
| Germany | 29 | 1 |
| France | 30 | 1 |
| The UK | 30 | 1 |
| Italy | 30 | 1 |
| Spain | 30 | 1 |
| Russia | 31 | 1 |
| Common European Union Patent System | 31 | 1 |
| Tendering | 32 | 1 |
| Regulatory Landscape for Biosimilars | 32 | 1 |
| The Future of Biosimilars is Advancing Along a Path Smoothened by European Groundwork | 32 | 1 |
| Japan | 33 | 1 |
| Generics | 33 | 1 |
| Transformation of the Generic Pharmaceutical Market | 33 | 1 |
| Registration and Pricing of Generic Drugs | 33 | 1 |
| Measures for Generic Growth | 33 | 1 |
| Biosimilar | 34 | 1 |
| Generic Growth Strategies - Major Strategies | 35 | 12 |
| Authorized Generics | 35 | 2 |
| Case Study | 37 | 1 |
| Mergers and Acquisitions | 37 | 2 |
| Vertical Integration | 39 | 1 |
| Therapeutic Expansion - Biosimilars | 39 | 1 |
| Outsourcing | 40 | 1 |
| Outsourcing Opportunities in Biosimilars | 40 | 1 |
| Outsourcing is Also a Source of Income for Generics Companies | 40 | 1 |
| Marketing Partnership | 41 | 1 |
| Case Studies | 41 | 1 |
| Marketing Partner DRL Increases Generic Fondaparinux s Sales in the US | 41 | 1 |
| Pfizer-Mylan Partnership Brings Generics into Japan | 41 | 1 |
| Prompt Launch of Lipitor Generic due to Collaboration Efforts Between Wockhardt and Ind-Swift | 41 | 1 |
| Paragraph IV Certifications | 42 | 1 |
| Case Studies | 42 | 1 |
| Example of a Paragraph IV Challenge That Did Not Work Out for a Generic | 42 | 1 |
| R&D Strategies Employed by Key Players in the Generics Market | 43 | 1 |
| Super Generics | 43 | 1 |
| Case Study | 43 | 1 |
| Biosimilars | 44 | 1 |
| Patent Protection around Biologic Drugs | 44 | 1 |
| The EU and the US Regulatory Pathways | 44 | 1 |
| Early Approvals - Limited to First Generation Products | 45 | 1 |
| Cost and Marketing of Biogenerics | 45 | 1 |
| Absence of Automatic Substitution is a Threat | 45 | 1 |
| Higher Development and Manufacturing Costs as Compared to Generics | 46 | 1 |
| Increasing Awareness and Acceptance | 46 | 1 |
| Generic Growth Strategies - Competitive Landscape | 47 | 26 |
| Teva Pharmaceutical Industries Limited | 47 | 1 |
| Overview | 47 | 1 |
| Revenue Analysis | 47 | 1 |
| Generics | 47 | 1 |
| Biosimilars | 47 | 1 |
| R&D | 47 | 1 |
| Therapeutic Focus | 48 | 1 |
| Geographic Focus | 48 | 1 |
| Generic Growth Strategies | 48 | 1 |
| Generic Approvals | 48 | 1 |
| Strong Pipeline | 48 | 1 |
| Geographic Expansion | 48 | 1 |
| Strategic Consolidations | 49 | 1 |
| New Product Launch | 49 | 1 |
| Infrastructure | 50 | 1 |
| SWOT | 51 | 1 |
| Sandoz | 52 | 1 |
| Overview | 52 | 1 |
| Revenue Analysis | 52 | 1 |
| Therapeutic Focus | 52 | 1 |
| Geographic Focus | 52 | 1 |
| Generic Growth Strategies | 53 | 1 |
| Strategic Consolidations | 53 | 1 |
| Pipeline Products | 53 | 1 |
| Launch Strategy | 53 | 1 |
| Biosimilar Development | 53 | 1 |
| SWOT | 54 | 1 |
| Mylan | 55 | 1 |
| Overview | 55 | 1 |
| Revenue Analysis | 55 | 1 |
| Therapeutic Focus | 55 | 1 |
| Geographic Focus | 55 | 1 |
| North America | 56 | 1 |
| EMEA | 56 | 1 |
| Japan | 56 | 1 |
| Generic Growth Strategies | 57 | 1 |
| Generic Drug Pipeline | 57 | 1 |
| Strategic Consolidations | 57 | 1 |
| New Product Launch | 57 | 1 |
| SWOT | 58 | 1 |
| Watson | 59 | 1 |
| Overview | 59 | 1 |
| Revenue Analysis | 59 | 1 |
| Therapeutic Focus | 59 | 1 |
| Geographic Focus | 59 | 1 |
| Generic Growth Strategies | 60 | 1 |
| Generic Drug Pipeline | 60 | 1 |
| New Product Launch | 60 | 1 |
| Infrastructure | 60 | 1 |
| Strategic Consolidations | 60 | 1 |
| SWOT | 61 | 1 |
| Actavis | 62 | 1 |
| Overview | 62 | 1 |
| Revenue Analysis | 62 | 1 |
| Therapeutic Focus | 62 | 1 |
| Geographic Focus | 62 | 1 |
| Generic Growth Strategies | 62 | 1 |
| Strategic Consolidations | 62 | 1 |
| New Product Launch | 62 | 1 |
| Infrastructure | 63 | 1 |
| SWOT | 63 | 1 |
| Hospira | 64 | 1 |
| Overview | 64 | 1 |
| Revenue Analysis | 64 | 1 |
| Therapeutic Focus | 64 | 1 |
| Geographic Focus | 64 | 1 |
| Generic Growth Strategies | 65 | 1 |
| Challenging Intellectual Property | 65 | 1 |
| Generic Drug Pipeline | 65 | 1 |
| New Product Launch | 65 | 1 |
| Generic Product Development | 65 | 1 |
| Strategic Consolidations | 65 | 1 |
| Biosimilar Product Development | 65 | 1 |
| SWOT | 66 | 1 |
| Sanofi | 67 | 1 |
| Overview | 67 | 1 |
| Revenue Analysis | 67 | 1 |
| Geographic Focus | 67 | 1 |
| Generic Growth Strategies | 67 | 1 |
| Strategic Consolidations | 67 | 1 |
| New Product Launch | 67 | 1 |
| SWOT | 68 | 1 |
| Daiichi Sankyo | 68 | 1 |
| Overview | 68 | 1 |
| Revenue Analysis | 68 | 1 |
| Geographic Focus | 68 | 1 |
| Generic Growth Strategies | 68 | 1 |
| SWOT | 69 | 1 |
| Aspen | 69 | 1 |
| Overview | 69 | 1 |
| Revenue Analysis | 69 | 1 |
| Geographic Focus | 69 | 1 |
| Generic Growth Strategies | 70 | 1 |
| Strategic Consolidations | 70 | 1 |
| New Product Launch | 70 | 1 |
| SWOT | 70 | 1 |
| STADA | 71 | 1 |
| Overview | 71 | 1 |
| Revenue Analysis | 71 | 1 |
| Therapeutic Focus | 71 | 1 |
| Geographic Focus | 71 | 1 |
| Generic Growth Strategies | 72 | 1 |
| SWOT | 72 | 1 |
| Generic Growth Strategies - Conclusion | 73 | 1 |
| Generic Growth Strategies - Appendix | 74 | 5 |
| Market Definitions | 74 | 1 |
| Abbreviations | 74 | 1 |
| Bibliography | 75 | 2 |
| Research Methodology | 77 | 2 |
| Coverage | 77 | 1 |
| Secondary Research | 77 | 1 |
| Primary Research | 78 | 1 |
| Expert Panel Validation | 78 | 1 |
| Contact Us | 78 | 1 |
| Disclaimer | 78 | 1 |